Chardan Capital analyst Geulah Livshits initiated coverage with a Buy rating on Homology Medicines (FIXX) today and set a price target of $34.00. The company’s shares closed last Monday at $17.68.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 7.4% and a 58.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Homology Medicines is a Strong Buy with an average price target of $32.50.
See today’s analyst top recommended stocks >>
Based on Homology Medicines’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $29.63 million. In comparison, last year the company had a GAAP net loss of $19 million.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FIXX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Read More on FIXX:
